Compare
Inhibrx Biosciences, Inc. vs Outlook Therapeutics, Inc. vs Pluri Inc. vs Humacyte, Inc.
| Latest fiscal year | Inhibrx Biosciences, Inc. INBX | Outlook Therapeutics, Inc. OTLK | Pluri Inc. PLUR | Humacyte, Inc. HUMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2026-06-30 | 2025-12-31 |
| Revenue | $1.30M | $1.41M | $1.02M | $2.04M |
| Revenue growth (YoY) | +550.0% | n/a | -24.0% | n/a |
| Gross margin | n/a | 4.0% | 44.6% | -376.1% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$140.06M | -$62.42M | -$23.82M | -$40.83M |
| EPS (Diluted) | -$9.04 | -$1.79 | -$2.44 | -$0.26 |
| Operating cash flow | -$129.79M | -$51.83M | -$19.59M | -$105.04M |
| Free cash flow | -$129.82M | n/a | -$20.22M | -$105.93M |
| Cash & equivalents | $124.22M | $8.08M | $3.53M | $50.50M |
| Total assets | $146.48M | $18.58M | $24.88M | $116.37M |
| Total liabilities | $138.49M | $50.77M | n/a | $113.26M |
| Shareholders' equity | $7.99M | -$32.19M | -$23.04M | $3.11M |
| Return on year-end equity | n/m | n/a | n/a | n/m |
| Shares outstanding | 14.58M | 53.89M | 10.82M | 193.00M |
Revenue, most recent five fiscal years
| Fiscal year | Inhibrx Biosciences, Inc. | Outlook Therapeutics, Inc. | Pluri Inc. | Humacyte, Inc. |
|---|---|---|---|---|
| Latest | $1.30M Ended 2025-12-31 | $1.41M Ended 2025-09-30 | $1.02M Ended 2026-06-30 | $2.04M Ended 2025-12-31 |
| 1 year earlier | $200.0K Ended 2024-12-31 | n/a | $1.34M Ended 2025-06-30 | $0 Ended 2024-12-31 |
| 2 years earlier | $1.80M Ended 2023-12-31 | n/a | $326.0K Ended 2024-06-30 | n/a |
| 3 years earlier | n/a | n/a | $287.0K Ended 2023-06-30 | n/a |
| 4 years earlier | n/a | n/a | $234.0K Ended 2022-06-30 | n/a |